Ethoxidol chewable tablets 100mg, No. 20

• ischemic heart disease (as part of complex therapy);

• complex therapy of ischemic stroke;

• encephalopathy;

• mild to moderate cognitive impairment.

EtoxidolЃ tablets are administered orally. The tablets are chewed and washed down with water.

For the complex therapy of coronary heart disease and the treatment of ischemic stroke , 100 mg (1 tablet) are prescribed 3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The maximum single dose is 200 mg: the daily dose is 800 mg. The course is at least 2 months, repeated courses - on the recommendation of a doctor. The duration of treatment and the choice of an individual dose depends on the severity of the patient's condition and the effectiveness of treatment.

In the complex therapy of mild and moderate cognitive disorders, the drug is prescribed without limiting the course of treatment in duration at a dose of 100 mg 3-4 times a day.

Active ingredient: ethylmethylhydroxypyridine malate - 100 mg

Excipients: acetylglutamic acid (N-acetyl L-glutamic acid) - 68 mg, deanol (2-dimethylaminoethanol) - 32 mg, glycine - 20 mg, microcrystalline cellulose - 260.1 mg, povidone (Kollidon 90F) - 1.6 mg, lactose monohydrate (milk sugar) - 36 mg, pregelatinized starch (starch 1500) - 30 mg, colloidal silicon dioxide (aerosil) - 9.5 mg, magnesium stearate - 6 mg, croscarmellose sodium (primellose) - 12.8 mg, sodium cyclamate - 18 mg, flavor orange (food flavoring 'Orange') - 6 mg.

• hypersensitivity to drug components;

• lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

• acute hepatic and / or renal failure;

• pregnancy, lactation period;

• age up to 18 years (efficacy and safety have not been established).

Clinical and pharmacological group: Antioxidant drug

Pharmaco-therapeutic group: Antioxidant

pharmachologic effect

EtoxidolЃ is an inhibitor of free radical processes, has a membrane-protective, antitoxic, nootropic, anticonvulsant, anxiolytic effect, increases the body's resistance to stress. EtoxidolЃ has anti-ischemic properties, improves blood flow in the ischemic zone, limits the zone of ischemic damage, exhibits a hypolipid effect, and reduces the content of total cholesterol and low density lipoproteins.

The drug increases the body's resistance to the effects of various damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol and antipsychotic drugs (neuroleptics) intoxication).

The drug improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis.

The mechanism of action of the drug is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GLMK, acetylcholine), which enhances their ability to bind to ligides, contributes to the preservation of the structural and functional organization of synomembranes and transport of neuromuscular cells.

Pharmacokinetics

After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract at an average rate of 0.569 ± 0.086 hours. On healthy volunteers, it was found that after oral administration of Ethoxidol tablets at a dose of 100 mg, Cmax in blood plasma is reached after 0.28 ± 0.08 hours and is 487.0 ± 72.4 ng / ml, followed by rapid elimination of the drug, with T1 / 2 = 1.46 ± 0.13 hours.

EthoxidolЃ is rapidly distributed throughout the organs and tissues of the body. Determined in blood plasma for 7-10 hours.

The drug is extensively metabolized in the liver to form phosphate-3-hydroxypyridine, glucuronoconjugated products.

Indications

• ischemic heart disease (as part of complex therapy);

• complex therapy of ischemic stroke;

• encephalopathy;

• mild to moderate cognitive impairment.

Dosage regimen

EtoxidolЃ tablets are administered orally. The tablets are chewed and washed down with water.

For the complex therapy of coronary heart disease and the treatment of ischemic stroke , 100 mg (1 tablet) are prescribed 3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The maximum single dose is 200 mg: the daily dose is 800 mg. The course is at least 2 months, repeated courses - on the recommendation of a doctor. The duration of treatment and the choice of an individual dose depends on the severity of the patient's condition and the effectiveness of treatment.

In the complex therapy of mild and moderate cognitive disorders, the drug is prescribed without limiting the course of treatment in duration at a dose of 100 mg 3-4 times a day.

Side effect

The drug is usually well tolerated. In rare cases, there may be allergic reactions, dyspeptic disorders, nausea and dry mouth, diarrhea, which quickly disappear on their own or when the drug is discontinued. With prolonged use, the manifestation of flatulence, sleep disturbances (drowsiness or disturbed falling asleep) is possible.

Contraindications for use

• hypersensitivity to drug components;

• lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

• acute hepatic and / or renal failure;

• pregnancy, lactation period;

• age up to 18 years (efficacy and safety have not been established).

Application during pregnancy and lactation

Etoxidol is contraindicated during pregnancy and during breastfeeding, since there have been no strictly controlled clinical studies of the safety of the drug during pregnancy and lactation.

Application for violations of liver function

Contraindicated in acute liver failure.

Application for impaired renal function

Contraindicated in acute renal failure.

Application in children

Contraindicated in children under 18 years of age.

special instructions

Influence on the ability to drive vehicles and use mechanisms

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

Due to the low toxicity of the drug, overdose is unlikely. In case of an accidental overdose, symptoms of sleep disturbance may occur - drowsiness, insomnia. Treatment is symptomatic.

Drug interactions

Enhances the effect of antiepileptic drugs (carbamazepine). antiparkinsonian drugs (levodopa) and benzodiazepine anxiolytics. Increases antianginal activity of nitro drugs and antihypertensive ACE inhibitors and beta-blockers. Reduces the toxic effects of ethyl alcohol.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life

Shelf life is 3 years.

Terms of sale

On prescription.